Metabolic syndrome

(Redirected from Metabolic Syndrome)
Jump to navigation Jump to search

For patient information click here

Metabolic syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Metabolic Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Dietary Therapy

Physical Activity

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Metabolic syndrome On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Metabolic syndrome

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Metabolic syndrome

CDC on Metabolic syndrome

Metabolic syndrome in the news

Blogs on Metabolic syndrome

Directions to Hospitals Treating Metabolic syndrome

Risk calculators and risk factors for Metabolic syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omar Elshafei, MD[2] Priyamvada Singh, M.B.B.S. [3]; Raviteja Guddeti, M.B.B.S. [4]; Aarti Narayan, M.B.B.S [5] Synonyms and keywords: Metabolic syndrome X; insulin resistance syndrome; Reaven syndrome; CHAOS (Australia); abdominal obesity-metabolic syndrome; dysmetabolic syndrome; plurimetabolic syndrome; hypertriglyceridemia waist syndrome; visceral fat syndrome; cardiometabolic syndrome; general cardiovascular syndrome

Overview

Metabolic syndrome is a clustering of interrelated cardiometabolic abnormalities that occur together more often than would be expected by chance: abdominal obesity, atherogenic dyslipidemia (raised triglycerides and reduced high-density lipoprotein cholesterol), raised blood pressure, and raised fasting glucose. Under the harmonized definition endorsed jointly by the International Diabetes Federation, the National Heart, Lung, and Blood Institute, the American Heart Association, the World Heart Federation, the International Atherosclerosis Society, and the International Association for the Study of Obesity, the presence of any three of these five components establishes the diagnosis, and no single component is obligatory.

The dominant pathophysiologic drivers are excess and dysfunctional adipose tissue, ectopic lipid deposition in liver and skeletal muscle, insulin resistance with compensatory hyperinsulinemia, and chronic low-grade inflammation. The syndrome is common, affects a large minority of adults in most surveyed populations, and is increasing in prevalence, with the sharpest rises in younger adults and in groups facing adverse social determinants of health.

Clinically, metabolic syndrome approximately doubles the risk of incident cardiovascular disease and cardiovascular death, increases all-cause mortality by roughly half, and confers a several-fold increase in the risk of incident type 2 diabetes mellitus. It is also associated with metabolic dysfunction-associated steatotic liver disease, chronic kidney disease, obstructive sleep apnea, polycystic ovary syndrome, and several common cancers.

The construct has been repositioned in contemporary practice. The American Heart Association now situates metabolic syndrome within a broader, staged cardiovascular-kidney-metabolic framework that runs from preserved health through excess adiposity, established metabolic risk factors or kidney disease, subclinical atherosclerosis, and finally clinical cardiovascular disease. This reframing matters because it aligns diagnosis with a life-course prevention strategy and with contemporary risk-prediction equations that incorporate kidney function.

No therapy has been shown to treat metabolic syndrome as a unitary entity. Management is therefore built on two pillars: intensive lifestyle intervention aimed at sustained weight reduction and increased physical activity, and guideline-directed treatment of each individual component to its own target. Incretin-based pharmacotherapy and metabolic surgery have altered this picture substantially, because they improve several components simultaneously and, in the case of semaglutide in patients with obesity and established cardiovascular disease, reduce hard cardiovascular outcomes.

Historical Perspective

  • The clustering of hypertension, hyperglycemia and gout was described by Kylin in 1923, and Vague drew attention in 1947 to the distinction between android (upper body) and gynoid (lower body) fat distribution and its differing metabolic consequences. Both observations are recounted in modern reviews of the syndrome.[1]
  • In his 1988 Banting Lecture, Reaven proposed that resistance to insulin-mediated glucose uptake was the common thread linking glucose intolerance, hyperinsulinemia, raised very low density lipoprotein triglyceride, reduced high-density lipoprotein cholesterol and hypertension, and named the cluster Syndrome X. Notably, obesity was not part of his original formulation.[2]
  • The World Health Organization produced the first formal diagnostic definition in 1998, making documented insulin resistance or a disorder of glucose regulation an obligatory requirement and including microalbuminuria as a component.[3]
  • The European Group for the Study of Insulin Resistance modified this definition in 1999, substituting fasting insulin in the upper quartile for clamp-derived insulin resistance, excluding patients with diabetes mellitus, and replacing body mass index and waist-to-hip ratio with waist circumference.[4]
  • The National Cholesterol Education Program Adult Treatment Panel III definition of 2001 dispensed with any obligatory component and with any requirement to measure insulin, which made the diagnosis feasible in routine practice and drove its widespread adoption.[5]
  • The American Heart Association and National Heart, Lung, and Blood Institute updated the Adult Treatment Panel III criteria in 2005, lowering the fasting glucose threshold to 100 mg/dL in line with the revised definition of impaired fasting glucose and clarifying that treated risk factors count toward the diagnosis.[6]
  • The International Diabetes Federation definition of 2005 and 2006 took the opposite position, making ethnicity-specific central obesity an obligatory component on the grounds that abdominal adiposity is the principal upstream driver.[7]
  • The competing definitions were reconciled in 2009 by a joint interim statement. Waist circumference was retained as a useful screening measurement but not made obligatory, three of five abnormal findings were agreed as sufficient, and a single set of cut points was adopted for every component except waist circumference, for which national or regional values continue to be used.[8]
  • The CardioMetabolic Health Alliance proposed in 2015 that the syndrome be treated as a chronic condition requiring a coordinated, staged, team-based care model rather than an isolated diagnostic label.[9]
  • In 2023 the American Heart Association issued a presidential advisory defining cardiovascular-kidney-metabolic syndrome and a five-stage staging system, positioning metabolic syndrome as one stage within a continuum that also encompasses chronic kidney disease and clinical cardiovascular disease.[10]
  • Two further nomenclature changes have direct bearing on this page. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis were renamed metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis by multisociety Delphi consensus in 2023,[11] and a 2025 Lancet Commission redefined obesity itself, distinguishing preclinical obesity from clinical obesity and recommending that body mass index no longer be used alone as a measure of individual health.[12]

Classification

Metabolic syndrome has no single agreed classification, and the literature contains several parallel schemes that answer different questions. Historically the schemes differed on one central issue: whether a single abnormality should be treated as the obligatory upstream driver of the cluster. The World Health Organization and the European Group for the Study of Insulin Resistance placed insulin resistance in that position, the International Diabetes Federation placed central obesity there, and the National Cholesterol Education Program declined to privilege any component. These are not merely academic differences, because they change which patients receive the label and therefore which patients are captured by prevalence estimates and by risk-factor screening programmes.[1][13]

For contemporary practice, four classification axes are relevant:

  • By diagnostic definition. The 2009 harmonized joint interim statement is the current standard for adults and should be used in preference to the earlier schemes, which are retained below for historical and comparative purposes.[8]
  • By population-specific anthropometry. Waist circumference thresholds vary by ethnicity and country, so the same measurement can be diagnostic in one population and normal in another.[8]
  • By disease stage. The American Heart Association cardiovascular-kidney-metabolic staging system places metabolic syndrome within a five-stage continuum that runs from preserved cardiometabolic health to clinical cardiovascular disease, and is the framework best suited to guiding treatment intensity.[10]
  • By age group. Separate pediatric criteria apply below the age of 16 years, and the diagnosis is not made at all below the age of 10 years.[14]

A practical consequence follows from the first two axes. Because prevalence figures, risk estimates and trial eligibility criteria published before 2009 mostly used the Adult Treatment Panel III or International Diabetes Federation definitions, older numbers are not directly interchangeable with those generated under the harmonized criteria, and the definition used should always be stated when a figure is quoted.[15]

Comparison of Diagnostic Definitions

Definition Obligatory component Components and thresholds Number required
World Health Organization, 1998[3] Insulin resistance (type 2 diabetes mellitus, impaired fasting glucose, impaired glucose tolerance, or glucose uptake in the lowest quartile on hyperinsulinemic euglycemic clamp) Blood pressure ≥140/90 mm Hg or antihypertensive treatment; triglycerides ≥1.7 mmol/L (150 mg/dL) and/or HDL-C <0.9 mmol/L (35 mg/dL) in men or <1.0 mmol/L (39 mg/dL) in women; body mass index >30 kg/m2 and/or waist-to-hip ratio >0.90 in men or >0.85 in women; urinary albumin excretion ≥20 µg/min or albumin-to-creatinine ratio ≥30 mg/g Insulin resistance plus 2 or more
European Group for the Study of Insulin Resistance, 1999[4] Hyperinsulinemia (fasting insulin in the upper 25% of the non-diabetic population); patients with diabetes mellitus excluded Fasting plasma glucose ≥6.1 mmol/L (110 mg/dL); blood pressure ≥140/90 mm Hg or treatment; triglycerides >2.0 mmol/L (177 mg/dL) or HDL-C <1.0 mmol/L (39 mg/dL) or treatment for dyslipidemia; waist circumference ≥94 cm in men or ≥80 cm in women Hyperinsulinemia plus 2 or more
NCEP Adult Treatment Panel III, 2001[5] None Waist circumference >102 cm in men or >88 cm in women; triglycerides ≥150 mg/dL; HDL-C <40 mg/dL in men or <50 mg/dL in women; blood pressure ≥130/85 mm Hg; fasting glucose ≥110 mg/dL 3 of 5
AHA/NHLBI update, 2005[6] None As for Adult Treatment Panel III, except that the fasting glucose threshold is lowered to ≥100 mg/dL and drug treatment of raised triglycerides, low HDL-C, raised blood pressure or raised glucose counts as a positive component 3 of 5
International Diabetes Federation, 2005-2006[7] Central obesity by ethnicity-specific waist circumference Triglycerides ≥150 mg/dL (1.7 mmol/L) or specific treatment; HDL-C <40 mg/dL (1.03 mmol/L) in men or <50 mg/dL (1.29 mmol/L) in women or specific treatment; blood pressure ≥130/85 mm Hg or treatment of previously diagnosed hypertension; fasting plasma glucose ≥100 mg/dL (5.6 mmol/L) or previously diagnosed type 2 diabetes mellitus Central obesity plus 2 or more
Harmonized joint interim statement, 2009[8] None Elevated waist circumference by population- and country-specific cut points; triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment; HDL-C <40 mg/dL (1.0 mmol/L) in men or <50 mg/dL (1.3 mmol/L) in women or drug treatment; systolic blood pressure ≥130 and/or diastolic ≥85 mm Hg, or antihypertensive drug treatment in a patient with a history of hypertension; fasting glucose ≥100 mg/dL (5.6 mmol/L) or drug treatment of elevated glucose 3 of 5

Waist Circumference Thresholds by Population

The harmonized statement retained population-specific waist circumference cut points because a single value could not be justified across ethnic groups.[8]

Population Men Women
Europid (International Diabetes Federation) ≥94 cm ≥80 cm
United States (AHA/NHLBI, Adult Treatment Panel III) ≥102 cm ≥88 cm
Canada and Europe (European cardiovascular societies) ≥94 cm ≥80 cm
South Asian ≥90 cm ≥80 cm
Chinese ≥90 cm ≥80 cm
Japanese (Japanese Obesity Society) ≥85 cm ≥90 cm
Sub-Saharan African Use Europid data Use Europid data
Eastern Mediterranean and Middle Eastern (Arab) Use Europid data Use Europid data
Ethnic South and Central American Use South Asian data Use South Asian data

Cardiovascular-Kidney-Metabolic Staging

The American Heart Association staging system places metabolic syndrome within a broader continuum and is intended to guide prevention across the life course.[10][16]

Stage Definition
Stage 0 No cardiovascular-kidney-metabolic risk factors: normal body mass index and waist circumference, normoglycemia, normotension, normal lipid profile, and no evidence of chronic kidney disease or cardiovascular disease
Stage 1 Excess or dysfunctional adiposity: overweight, obesity, abdominal obesity, or dysfunctional adipose tissue manifesting as impaired fasting glucose or prediabetes, without other metabolic risk factors or chronic kidney disease
Stage 2 Metabolic risk factors or chronic kidney disease: hypertriglyceridemia, hypertension, metabolic syndrome, diabetes mellitus, or chronic kidney disease
Stage 3 Subclinical cardiovascular disease in the presence of cardiovascular-kidney-metabolic risk: subclinical atherosclerosis or subclinical heart failure, or risk equivalents such as very high predicted cardiovascular risk or very high-risk chronic kidney disease
Stage 4 Clinical cardiovascular disease in the presence of cardiovascular-kidney-metabolic risk: myocardial infarction and other atherosclerotic disease, heart failure, atrial fibrillation, stroke, or peripheral artery disease. Stage 4a denotes the absence of kidney failure and stage 4b its presence

Metabolic Syndrome in Children and Adolescents

The International Diabetes Federation recommends that the diagnosis not be made below the age of 10 years, that in children aged 10 to less than 16 years central obesity defined by a waist circumference at or above the 90th percentile be obligatory together with adult-type thresholds for the remaining components, and that adult criteria be applied from age 16 years onward.[14]

Controversies in Classification

  • A joint statement of the American Diabetes Association and the European Association for the Study of Diabetes argued that the criteria were ambiguous and incomplete, that the rationale for the thresholds was ill defined, that the inclusion of patients with established diabetes mellitus was illogical, and that the cardiovascular risk conveyed by the syndrome appeared to be no greater than the sum of its parts. The authors concluded that clinicians should evaluate and treat each risk factor individually.[13]
  • Reaven himself questioned whether the diagnosis was necessary, noting that dichotomizing continuous variables discards information and that a positive label adds little to individualized risk assessment.[17]
  • The counterargument, reflected in the harmonized statement and in the cardiovascular-kidney-metabolic advisory, is that the label has value as a simple, inexpensive prompt to comprehensive risk assessment and early lifestyle intervention, particularly in primary care.[8][10]

Pathophysiology

  • The unifying abnormality is resistance to insulin-mediated glucose disposal with compensatory hyperinsulinemia. When beta cell compensation eventually fails, glucose intolerance and then type 2 diabetes mellitus supervene.[2][1]
  • Mechanistically, insulin resistance in skeletal muscle and liver is driven principally by ectopic accumulation of lipid intermediates. Diacylglycerol-mediated activation of protein kinase C isoforms impairs insulin receptor substrate signaling in muscle and hepatic insulin receptor kinase activity in liver, while increased hepatic acetyl-coenzyme A promotes gluconeogenesis.[18]
  • Expansion and dysfunction of visceral and ectopic adipose depots increases the flux of free fatty acids to the liver, promotes secretion of pro-inflammatory adipokines and reduces adiponectin. The result is a chronic low-grade inflammatory state with recruitment of macrophages to adipose tissue.[19]
  • Hepatic overproduction of very low density lipoprotein generates the characteristic atherogenic lipid triad of raised triglycerides, reduced high-density lipoprotein cholesterol and a preponderance of small dense low-density lipoprotein particles.[6][1]
  • Blood pressure rises through several converging mechanisms: sympathetic nervous system activation, activation of the renin-angiotensin-aldosterone system by adipose-derived mediators, renal sodium retention promoted by hyperinsulinemia, and endothelial dysfunction with reduced nitric oxide bioavailability.[6][19]
  • The same processes underlie the strong associations with metabolic dysfunction-associated steatotic liver disease, chronic kidney disease and subclinical atherosclerosis, which is the rationale for the integrated cardiovascular-kidney-metabolic construct.[10][16]
 
Positive energy balance and genetic susceptibility
 
 
 
 
 
 
 
 
Expansion and dysfunction of visceral and ectopic adipose tissue
 
 
 
 
 
 
 
 
Increased free fatty acid flux, altered adipokines, low-grade inflammation
 
 
 
 
 
 
 
 
Hepatic and skeletal muscle insulin resistance with compensatory hyperinsulinemia
 
 
 
 
 
 
 
 
Atherogenic dyslipidemia, raised blood pressure, raised fasting glucose
 
 
 
 
 
 
 
 
Type 2 diabetes mellitus, atherosclerosis, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease
 

Causes

Primary Drivers

  • Sustained positive energy balance with excess or dysfunctional adiposity, particularly visceral and ectopic fat[19][12]
  • Physical inactivity and sedentary behavior[6]
  • Genetic and epigenetic susceptibility, including ethnic differences in the visceral adiposity accompanying any given body mass index[8]
  • Aging, with progressive loss of lean mass and redistribution of fat[6]

Secondary and Associated Causes

  • Cushing's syndrome and exogenous glucocorticoid exposure[20]
  • Polycystic ovary syndrome[21]
  • Congenital and acquired lipodystrophy syndromes, including antiretroviral-associated lipodystrophy[22]
  • Obstructive sleep apnea and short or disrupted sleep[16]
  • Drug-induced metabolic disturbance, most prominently with second-generation antipsychotics, where clozapine and olanzapine carry the greatest burden of weight gain and lipid and glucose derangement[23]
  • Adverse social determinants of health, including food insecurity, unemployment and low household income, which are independently associated with more advanced cardiovascular-kidney-metabolic disease[24]

Differentiating Metabolic Syndrome from other Diseases

Metabolic syndrome is a diagnosis of clustering, not of exclusion, but several conditions reproduce the same phenotype and carry different management implications. The table below summarizes the principal alternatives.

Condition Features favoring the alternative diagnosis Confirmatory evaluation
Cushing's syndrome Proximal myopathy, wide violaceous striae, easy bruising, facial plethora, dorsocervical and supraclavicular fat pads, osteoporosis, rapid onset, hypokalemia Late-night salivary cortisol, 1 mg overnight dexamethasone suppression test, or 24-hour urinary free cortisol, with two abnormal tests before proceeding to cause-specific evaluation[20]
Familial partial lipodystrophy and generalized lipodystrophy Selective loss of subcutaneous fat with muscular appearance, acanthosis nigricans, severe hypertriglyceridemia out of proportion to body mass index, early and refractory diabetes mellitus, hepatomegaly, eruptive xanthomas Clinical fat distribution assessment, leptin level, genetic testing (for example LMNA and PPARG), and specialist referral[22]
Polycystic ovary syndrome Oligo-ovulation or anovulation, clinical or biochemical hyperandrogenism, infertility, onset around menarche Androgen profile, exclusion of other causes of hyperandrogenism, pelvic ultrasound or anti-Müllerian hormone where criteria require it[21]
Hypothyroidism Fatigue, cold intolerance, constipation, weight gain with slow pulse, delayed relaxation of reflexes, raised low-density lipoprotein with only modest triglyceride elevation Thyroid stimulating hormone and free thyroxine
Acromegaly Acral enlargement, coarsened features, macroglossia, carpal tunnel syndrome, sleep apnea, progressive cardiomyopathy Insulin-like growth factor 1, oral glucose tolerance test with growth hormone suppression, pituitary magnetic resonance imaging
Familial combined hyperlipidemia and familial hypertriglyceridemia Strong family history of premature coronary artery disease, marked lipid abnormalities with normal waist circumference and normal glycemia Fasting lipid profile in first-degree relatives, apolipoprotein B, exclusion of secondary causes
Primary aldosteronism and other secondary hypertension Resistant or early-onset hypertension, spontaneous or diuretic-induced hypokalemia, adrenal incidentaloma Plasma aldosterone-to-renin ratio, confirmatory suppression testing, adrenal computed tomography
Obstructive sleep apnea Loud snoring, witnessed apneas, unrefreshing sleep, morning headache, resistant hypertension with non-dipping nocturnal pattern Polysomnography or home sleep apnea testing
Antipsychotic-induced metabolic disturbance Temporal relationship to initiation or dose escalation of a second-generation antipsychotic, rapid weight gain Medication review, comparison against agent-specific metabolic risk, consideration of switching where clinically feasible[23]
Metabolic dysfunction-associated steatotic liver disease Hepatic steatosis on imaging with at least one cardiometabolic criterion, raised transaminases, exclusion of significant alcohol intake and other liver disease Liver ultrasound or transient elastography, non-invasive fibrosis scores, alcohol history[11]
Established type 2 diabetes mellitus Glycemia already in the diabetic range; the metabolic syndrome label adds little to management once diabetes is diagnosed Fasting glucose, glycated hemoglobin, oral glucose tolerance test[13]

Epidemiology and Demographics

  • In the United States National Health and Nutrition Examination Survey, the prevalence of metabolic syndrome among adults aged 20 years and older increased from 37.6% (95% CI 34.0%-41.4%) in 2011-12 to 41.8% (95% CI 38.1%-45.7%) in 2017-18. The prevalence of the elevated glucose component rose over the same interval from 48.9% (95% CI 45.7%-52.5%) to 64.7% (95% CI 61.4%-67.9%), and prevalence among participants with low educational attainment rose from 44.4% (95% CI 38.8%-50.1%) to 55.0% (95% CI 50.8%-59.1%).[25]
  • An earlier analysis of the same survey covering 2011 to 2016 also documented rising prevalence, with the steepest relative increases among younger adults, which is of particular concern given the long exposure time to risk.[26]
  • Applying the cardiovascular-kidney-metabolic staging system to United States adults aged 30 to 79 years, the age-standardized prevalence of stages 0 through 4 was 13.6% (95% CI 13.0%-14.3%), 29.9% (95% CI 29.1%-30.7%), 43.7% (95% CI 42.9%-44.5%), 4.7% (95% CI 4.4%-5.0%) and 8.1% (95% CI 7.6%-8.5%) respectively. Advanced disease (stage 3 or 4) was more prevalent among those who were unemployed (18.8%, 95% CI 17.7%-20.1%, versus 11.4%, 95% CI 11.0%-11.9%), had low family income (16.1%, 95% CI 15.4%-16.8%, versus 10.1%, 95% CI 9.5%-10.7%) or experienced food insecurity (18.3%, 95% CI 17.1%-19.6%, versus 11.7%, 95% CI 11.2%-12.2%).[24]
  • An independent analysis of the 2011 to 2020 survey cycles similarly found that the large majority of United States adults meet criteria for at least stage 1 disease, with meaningful differences by race and ethnicity.[27]
  • In children and adolescents, modelled global prevalence in 2020 was 2.8% (95% uncertainty interval 1.4-6.7) among children aged 6 to 12 years and 4.8% (95% uncertainty interval 2.9-8.5) among adolescents aged 13 to 18 years, corresponding to approximately 25.8 million (12.6-61.0) children and 35.5 million (21.3-63.0) adolescents. Regional prevalence in children ranged from 1.4% (0.6-3.1) in northwestern Europe to 8.2% (6.9-10.1) in Central Latin America, and in adolescents from 2.9% (2.6-3.3) in east Asia to 6.7% (5.9-8.3) in high-income English-speaking countries. Prevalence did not rise consistently with national income, indicating that country wealth is not the principal driver.[28]
  • Population-level burden of the constituent risk factors and their trends are tracked annually in the American Heart Association statistical update.[29]

Risk Factors

Non-modifiable

Modifiable

  • Excess and centrally distributed adiposity[19][12]
  • Physical inactivity and prolonged sedentary time[31]
  • Diets high in refined carbohydrate, sugar-sweetened beverages and ultra-processed foods[32]
  • Cigarette smoking and short or poor-quality sleep, both included in the Life's Essential 8 cardiovascular health construct[32]
  • Second-generation antipsychotic and long-term glucocorticoid therapy[23]
  • Adverse social determinants of health, including food insecurity and low income[24]

Screening

  • There is no recommendation to screen the general population for metabolic syndrome as a discrete entity. Screening is instead directed at its components and at global cardiovascular risk.[13][33]
  • The United States Preventive Services Task Force recommends screening for prediabetes and type 2 diabetes mellitus in adults aged 35 to 70 years who have overweight or obesity, and referral of those with abnormal results to preventive interventions (B recommendation).[34]
  • The Task Force also recommends offering or referring adults with a body mass index of 30 kg/m2 or higher to intensive multicomponent behavioral interventions (B recommendation),[35] and recommends initiating a statin in adults aged 40 to 75 years who have one or more cardiovascular risk factors and an estimated 10-year cardiovascular risk of 10% or greater (B recommendation), with selective offering where estimated risk is 7.5% to less than 10% (C recommendation).[36]
  • The practical screening panel therefore comprises waist circumference, blood pressure measured with correct technique, a fasting lipid profile, and fasting glucose or glycated hemoglobin. Assessment of kidney function with estimated glomerular filtration rate and urinary albumin-to-creatinine ratio is added in the cardiovascular-kidney-metabolic framework, since kidney disease defines stage 2 and modifies risk prediction.[10]
  • Global risk should be quantified with a contemporary equation. The American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations estimate 10-year and 30-year risk of total cardiovascular disease, atherosclerotic cardiovascular disease and heart failure in adults aged 30 to 79 years, are sex-specific and race-free, incorporate estimated glomerular filtration rate, and optionally accept urinary albumin-to-creatinine ratio, glycated hemoglobin and a social deprivation index. In external validation the median C-statistic for total cardiovascular disease was 0.794 (interquartile interval 0.763-0.809) in female and 0.757 (interquartile interval 0.727-0.778) in male participants.[37]

Natural History, Complications and Prognosis

  • Metabolic syndrome typically develops over years, beginning with weight gain and central fat accumulation, progressing through isolated abnormalities of triglycerides or blood pressure, and culminating in the full cluster. Progression to type 2 diabetes mellitus occurs when beta cell compensation for insulin resistance fails.[1][2]
  • In a meta-analysis of 87 studies including 951,083 patients, metabolic syndrome was associated with a relative risk of 2.35 (95% CI 2.02 to 2.73) for cardiovascular disease, 2.40 (95% CI 1.87 to 3.08) for cardiovascular mortality, 1.58 (95% CI 1.39 to 1.78) for all-cause mortality, 1.99 (95% CI 1.61 to 2.46) for myocardial infarction and 2.27 (95% CI 1.80 to 2.85) for stroke. Patients with the syndrome but without diabetes mellitus retained a high cardiovascular risk.[38]
  • An earlier meta-analysis of 37 studies comprising 43 cohorts and 172,573 individuals found a relative risk of cardiovascular events and death of 1.78 (95% CI 1.58 to 2.00), which remained elevated at 1.54 (95% CI 1.32 to 1.79) after adjustment for traditional cardiovascular risk factors. The association was stronger in women and in lower-risk populations.[39]
  • Pooled prospective data using the exact Adult Treatment Panel III definition gave relative risks of 1.27 (95% CI 0.90 to 1.78) for all-cause mortality, 1.65 (95% CI 1.38 to 1.99) for cardiovascular disease and 2.99 (95% CI 1.96 to 4.57) for diabetes mellitus. The corresponding population-attributable fractions were approximately 6% to 7% for all-cause mortality, 12% to 17% for cardiovascular disease and 30% to 52% for diabetes.[15]
  • Cancer risk is also increased. In cohort studies, metabolic syndrome was associated in men with liver (relative risk 1.43), colorectal (1.25) and bladder cancer (1.10), and in women with endometrial (1.61), pancreatic (1.58), postmenopausal breast (1.56), rectal (1.52) and colorectal cancer (1.34).[40]
  • Additional recognized complications include metabolic dysfunction-associated steatotic liver disease with progression to steatohepatitis, fibrosis and cirrhosis,[11] chronic kidney disease,[10] obstructive sleep apnea, hyperuricemia and gout, and reproductive dysfunction.[6][21]
  • Prognosis improves substantially with weight reduction and component control, and the syndrome is frequently reversible in its earlier stages.[41]

Diagnosis

Diagnostic Criteria | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings |Other Diagnostic Studies

Diagnostic Criteria

The harmonized criteria are the current standard. Any three of the five components below establish the diagnosis, and drug treatment of a component counts as a positive finding.[8]

Component Threshold
Elevated waist circumference Population- and country-specific cut points (see the classification table above)
Elevated triglycerides ≥150 mg/dL (1.7 mmol/L), or drug treatment for elevated triglycerides
Reduced high-density lipoprotein cholesterol <40 mg/dL (1.0 mmol/L) in males and <50 mg/dL (1.3 mmol/L) in females, or drug treatment for reduced HDL-C
Elevated blood pressure Systolic ≥130 mm Hg and/or diastolic ≥85 mm Hg, or antihypertensive drug treatment in a patient with a history of hypertension
Elevated fasting glucose ≥100 mg/dL (5.6 mmol/L), or drug treatment of elevated glucose
 
 
Adult with central obesity, raised blood pressure, dyslipidemia or prediabetes
 
 
 
 
 
 
 
 
 
 
 
 
Measure all five harmonized components
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 or more components abnormal
 
Fewer than 3 components abnormal
 
 
 
 
 
 
 
 
 
 
Metabolic syndrome confirmed: exclude secondary causes and assign cardiovascular-kidney-metabolic stage
 
No metabolic syndrome: treat any abnormal components and reassess periodically
 

History and Symptoms

  • Metabolic syndrome is usually asymptomatic and is detected through measurement rather than symptoms.[6]
  • The history should cover weight trajectory and previous weight-loss attempts, dietary pattern, physical activity and sedentary time, sleep duration and symptoms of obstructive sleep apnea, alcohol and tobacco use, menstrual and reproductive history, family history of premature cardiovascular disease and diabetes mellitus, and a full medication review including antipsychotics, glucocorticoids and antiretroviral agents.[6][23]
  • Symptoms suggesting an alternative or superimposed diagnosis should be sought explicitly, including proximal weakness and easy bruising, cold intolerance, acral enlargement, and oligomenorrhea with hirsutism.[20][21]

Physical Examination

  • Waist circumference measured at the top of the iliac crest at the end of a normal expiration, with a non-stretch tape held horizontally and snug without compressing the skin.[8]
  • Height, weight and body mass index, recognizing that body mass index alone is an inadequate individual measure of adiposity and should be paired with an anthropometric measure of fat distribution.[12]
  • Blood pressure using validated equipment and correct technique, with out-of-office confirmation before a diagnosis of hypertension is made.[42]
  • Skin examination for acanthosis nigricans, skin tags, eruptive xanthomas and xanthelasma, and for the violaceous striae and centripetal fat redistribution of Cushing's syndrome.[20]
  • Assessment of fat distribution for the selective subcutaneous fat loss of lipodystrophy, and examination for hepatomegaly.[22]

Laboratory Findings

  • Core panel: fasting lipid profile (total cholesterol, triglycerides, high-density lipoprotein cholesterol and calculated or measured low-density lipoprotein cholesterol), fasting plasma glucose, and glycated hemoglobin.[8][30]
  • Kidney assessment: serum creatinine with estimated glomerular filtration rate and urinary albumin-to-creatinine ratio, which are required for cardiovascular-kidney-metabolic staging and improve risk prediction, particularly where albuminuria exceeds 300 mg/g.[10][37]
  • Liver assessment: alanine aminotransferase and aspartate aminotransferase, with non-invasive fibrosis scoring where steatosis is present.[11]
  • Selective testing directed by clinical suspicion: thyroid stimulating hormone, overnight dexamethasone suppression or late-night salivary cortisol, androgen profile, insulin-like growth factor 1, and serum uric acid.[20][21]
  • Measurement of fasting insulin or formal quantification of insulin resistance is not required for the harmonized diagnosis and is generally reserved for research.[8]

Electrocardiogram

Chest X Ray

  • A chest x ray has no role in establishing the diagnosis. It is obtained where symptoms suggest heart failure or other cardiopulmonary disease.[6]

CT

  • Computed tomography quantifies visceral and subcutaneous adipose tissue accurately and has been central to research defining the metabolic consequences of fat distribution, but it is not recommended for routine diagnosis because of cost and radiation exposure.[19]
  • Coronary artery calcium scoring by non-contrast computed tomography may be used as a risk-refining test in selected adults at intermediate estimated risk, and a positive result places the patient in the subclinical cardiovascular disease stage of the cardiovascular-kidney-metabolic framework.[33][10]

MRI

  • Magnetic resonance imaging and magnetic resonance spectroscopy quantify visceral, hepatic and intramyocellular lipid and remain the reference standards for ectopic fat measurement in research settings.[18][19]
  • Magnetic resonance imaging proton density fat fraction and magnetic resonance elastography are used in specialist hepatology practice and in clinical trials of steatohepatitis.[11]

Echocardiography or Ultrasound

Other Imaging Findings

  • Dual-energy x-ray absorptiometry can quantify total and regional body fat and is one of the direct measures of adiposity endorsed for confirming excess adiposity when available.[12]

Other Diagnostic Studies

Treatment

Dietary Therapy | Physical Activity | Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Tertiary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

No agent has been licensed to treat metabolic syndrome as a single entity, and the evidence base is component-directed. The two therapeutic pillars are sustained lifestyle change with weight reduction, and guideline-directed treatment of each abnormal component.[6][13]

 
Metabolic syndrome confirmed (cardiovascular-kidney-metabolic stage 2)
 
 
 
 
 
 
 
 
Step 1. Intensive lifestyle intervention: 7% or greater weight loss target, 150 minutes or more of moderate-intensity activity per week, Mediterranean or DASH dietary pattern, tobacco cessation, sleep optimization
 
 
 
 
 
 
 
 
Step 2. Treat each component to its own guideline target: blood pressure, low-density lipoprotein cholesterol and triglycerides, glycemia, albuminuria
 
 
 
 
 
 
 
 
Step 3. Add weight-centric pharmacotherapy where indicated by body mass index and comorbidity; prefer agents with cardiovascular or kidney outcome benefit
 
 
 
 
 
 
 
 
Step 4. Consider metabolic and bariatric surgery where criteria are met and response to steps 1 to 3 is inadequate
 
 
 
 
 
 
 
 
Ongoing surveillance: annual reassessment of all five components, kidney function, hepatic steatosis and fibrosis, and global cardiovascular risk
 

Initial Management

  • Intensive lifestyle intervention is first-line for every patient. In the Diabetes Prevention Program, 3,234 participants with impaired glucose tolerance were randomized to placebo, metformin 850 mg twice daily, or a lifestyle programme targeting at least 7% weight loss and at least 150 minutes of physical activity per week. Over an average of 2.8 years the incidence of diabetes mellitus was 11.0, 7.8 and 4.8 cases per 100 person-years respectively; lifestyle reduced incidence by 58% (95% CI 48 to 66) and metformin by 31% (95% CI 17 to 43) compared with placebo.[43]
  • The same trial provides the most direct randomized evidence for treating metabolic syndrome itself. Fifty-three percent of participants (n = 1,711) met Adult Treatment Panel III criteria at baseline. Among the remainder, the incidence of the syndrome was reduced by 41% in the lifestyle group (P < 0.001) and by 17% in the metformin group (P = 0.03) compared with placebo, with three-year cumulative incidences of 51%, 45% and 34% in the placebo, metformin and lifestyle groups respectively.[41]
  • Benefit is durable. Long-term follow-up of the Diabetes Prevention Program Outcomes Study showed persistent reductions in diabetes incidence in both the lifestyle and metformin groups over 15 years.[44]
  • The Finnish Diabetes Prevention Study independently demonstrated that individualized counselling on weight reduction, dietary fat and fibre, and physical activity substantially reduced progression from impaired glucose tolerance to diabetes mellitus.[45]
  • Dietary pattern matters more than any single macronutrient target. A Mediterranean-style diet reduced the prevalence of metabolic syndrome and improved endothelial function in a randomized trial of patients meeting Adult Treatment Panel III criteria,[46] and in the PREDIMED trial a Mediterranean diet supplemented with extra-virgin olive oil or mixed nuts reduced major cardiovascular events compared with a reduced-fat control diet (hazard ratio 0.69, 95% CI 0.53 to 0.91 and 0.72, 95% CI 0.54 to 0.95 respectively).[47]
  • The DASH dietary pattern, rich in fruit, vegetables and low-fat dairy products and reduced in saturated and total fat, lowers blood pressure substantially and is an appropriate alternative or complement.[48]
  • Physical activity should target at least 150 to 300 minutes of moderate-intensity or 75 to 150 minutes of vigorous-intensity aerobic activity per week, with muscle-strengthening activity on two or more days per week and reduction of sedentary time.[31]
  • An important caveat should be stated plainly. In the Look AHEAD trial, 5,145 overweight or obese adults with type 2 diabetes mellitus were randomized to intensive lifestyle intervention or diabetes support and education. Despite greater weight loss (8.6% versus 0.7% at 1 year and 6.0% versus 3.5% at study end) and better risk-factor control, the primary cardiovascular composite occurred at 1.83 versus 1.92 events per 100 person-years (hazard ratio 0.95, 95% CI 0.83 to 1.09, P = 0.51) and the trial was stopped for futility at a median follow-up of 9.6 years.[49]

Medical Therapy

Blood pressure

  • Treat according to the 2025 multisociety high blood pressure guideline, which retires and replaces the 2017 guideline. Lifestyle measures are foundational, and pharmacologic therapy is guided by blood pressure stage and estimated cardiovascular risk, with team-based care and out-of-office monitoring emphasized.[42]
  • Agents with favorable or neutral metabolic profiles are generally preferred as initial therapy in this population.[6]

Lipids

  • Low-density lipoprotein cholesterol is the primary target, with statin intensity determined by clinical atherosclerotic cardiovascular disease status, LDL-C level, diabetes mellitus and estimated 10-year risk, and with risk-enhancing factors used to guide decisions in the intermediate-risk group.[50]
  • Statin therapy is associated with a small increase in incident diabetes mellitus (odds ratio 1.09, 95% CI 1.02 to 1.17), amounting to one extra case for 255 patients (95% CI 150 to 852) treated for 4 years. This risk is small in absolute terms and is outweighed by the reduction in coronary events, and it should not change practice in patients at moderate or high cardiovascular risk or with established cardiovascular disease.[51]

Glycemia and diabetes prevention

  • Metformin may be considered for diabetes prevention in selected high-risk individuals, particularly those with body mass index of 35 kg/m2 or higher, younger age, or prior gestational diabetes, as set out in the American Diabetes Association Standards of Care.[30][43]
  • In patients who have progressed to type 2 diabetes mellitus, agent selection should be driven by cardiovascular and kidney comorbidity rather than by glucose lowering alone.[52]
  • Glucagon-like peptide-1 receptor agonists reduce major adverse cardiovascular events, cardiovascular death and kidney outcomes in patients with type 2 diabetes mellitus in meta-analysis of cardiovascular outcome trials.[53]
  • Sodium-glucose cotransporter 2 inhibitors slow progression of chronic kidney disease and reduce cardiovascular events across a broad range of patients with and without diabetes.[54]
  • Pioglitazone is the only agent tested against insulin resistance itself as the therapeutic target in a cardiovascular outcome trial. In the Insulin Resistance Intervention after Stroke trial, 3,876 patients without diabetes who had a recent ischemic stroke or transient ischemic attack and a homeostasis model assessment of insulin resistance index above 3.0 were randomized to pioglitazone or placebo. By 4.8 years the primary outcome of fatal or non-fatal stroke or myocardial infarction occurred in 175 of 1,939 patients (9.0%) versus 228 of 1,937 (11.8%) (hazard ratio 0.76, 95% CI 0.62 to 0.93, P = 0.007), and diabetes developed in 73 patients (3.8%) versus 149 (7.7%) (hazard ratio 0.48, 95% CI 0.33 to 0.69, P < 0.001). Pioglitazone caused more weight gain exceeding 4.5 kg (52.2% versus 33.7%, P < 0.001), edema (35.6% versus 24.9%, P < 0.001) and fracture requiring surgery or hospitalization (5.1% versus 3.2%, P = 0.003).[55]

Weight-centric pharmacotherapy

  • Obesity pharmacotherapy is indicated as an adjunct to lifestyle intervention according to body mass index and the presence of weight-related complications, with agent selection individualized to comorbidity.[56]
  • In the STEP 1 trial, once-weekly subcutaneous semaglutide 2.4 mg produced a mean change in body weight of -14.9% versus -2.4% with placebo at week 68 in adults with overweight or obesity without diabetes, with improvement in waist circumference, blood pressure and lipids.[57]
  • In SURMOUNT-1, tirzepatide produced mean weight reductions of -15.0%, -19.5% and -20.9% at the 5 mg, 10 mg and 15 mg doses versus -3.1% with placebo at 72 weeks.[58] Comparable, somewhat smaller reductions were seen in SURMOUNT-2 in patients with type 2 diabetes mellitus.[59]
  • Most importantly for this population, the SELECT trial showed that once-weekly semaglutide 2.4 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke in patients with overweight or obesity and pre-existing cardiovascular disease but without diabetes (hazard ratio 0.80, 95% CI 0.72 to 0.90). This is the first demonstration that treating the adiposity component improves hard cardiovascular outcomes independently of glucose lowering.[60]

Procedural / Surgical Therapy

  • Metabolic and bariatric surgery should be considered where response to lifestyle and pharmacologic therapy is inadequate. The 2022 American Society for Metabolic and Bariatric Surgery and International Federation for the Surgery of Obesity and Metabolic Disorders statement recommends surgery for individuals with body mass index of 35 kg/m2 or greater regardless of comorbidity, and for individuals with body mass index of 30 to 34.9 kg/m2 with metabolic disease, and endorses lower thresholds in Asian populations. These criteria supersede the 1991 National Institutes of Health consensus thresholds.[61]
  • In the STAMPEDE trial, Roux-en-Y gastric bypass and sleeve gastrectomy were superior to intensive medical therapy alone for glycemic control, weight loss and medication reduction at 5 years in patients with type 2 diabetes mellitus and obesity.[62]
  • The Swedish Obese Subjects study, a prospective matched intervention trial, demonstrated that bariatric surgery reduced overall mortality[63] and the incidence of cardiovascular events compared with usual care.[64]

Long-Term Management

  • Metabolic syndrome should be managed as a chronic condition with structured, team-based follow-up rather than as an incidental finding.[9][10]
  • Annual reassessment should include all five components, weight and waist circumference, estimated glomerular filtration rate and urinary albumin-to-creatinine ratio, hepatic enzymes with non-invasive fibrosis assessment where steatosis is present, and recalculation of global cardiovascular risk.[10][37][11]
  • Weight regain after discontinuation of pharmacotherapy is expected, and treatment should be planned as long-term rather than time-limited.[56]
  • Population-level maintenance of cardiovascular health is usefully framed by the Life's Essential 8 metrics, which combine diet, physical activity, nicotine exposure, sleep, weight, lipids, glucose and blood pressure.[32]
  • European guidance offers a stepwise risk-based approach to prevention that is broadly concordant with North American recommendations and may be preferred in some settings.[65]

Special Populations

Chronic kidney disease

  • Chronic kidney disease defines cardiovascular-kidney-metabolic stage 2 and markedly amplifies risk. Management should follow the KDIGO 2024 guideline, including risk-based use of renin-angiotensin system blockade, sodium-glucose cotransporter 2 inhibition and statin therapy.[66][67]

Metabolic dysfunction-associated steatotic liver disease

  • Steatotic liver disease is now defined by hepatic steatosis together with at least one cardiometabolic criterion, so most patients with metabolic syndrome and steatosis meet the definition.[11]
  • In the phase 3 ESSENCE trial, 1,197 patients with biopsy-defined steatohepatitis and stage 2 or 3 fibrosis were randomized 2:1 to once-weekly semaglutide 2.4 mg or placebo. At the week 72 interim analysis of the first 800 patients, resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% versus 34.3% (estimated difference 28.7 percentage points, 95% CI 21.1 to 36.2, P < 0.001), and reduction in fibrosis without worsening of steatohepatitis in 36.8% versus 22.4% (estimated difference 14.4 percentage points, 95% CI 7.5 to 21.3, P < 0.001). Mean body-weight change was -10.5% versus -2.0%.[68]
  • Resmetirom, a liver-directed thyroid hormone receptor beta agonist, improved both steatohepatitis resolution and fibrosis in the MAESTRO-NASH trial and represents the first agent approved specifically for this indication.[69]

Women with polycystic ovary syndrome

Children and adolescents

  • The diagnosis should not be applied below age 10 years. Management is centred on family-based lifestyle intervention, and the high absolute numbers of affected young people worldwide argue for multisectoral prevention rather than individual treatment alone.[14][28]

Patients receiving antipsychotic therapy

  • Baseline and serial monitoring of weight, waist circumference, blood pressure, fasting glucose and lipids is required, and agent selection should take account of large differences between drugs in metabolic burden.[23]

Patients with lipodystrophy or Cushing's syndrome

  • These patients require disease-specific therapy directed at the underlying disorder, since conventional lifestyle and lipid-lowering approaches alone are usually insufficient.[22][20]

Case Studies

Case #1

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 Eckel RH, Grundy SM, Zimmet PZ (April 2005). "The metabolic syndrome". Lancet. 365 (9468): 1415–28. doi:10.1016/S0140-6736(05)66378-7. PMID 15836891.
  2. ↑ 2.0 2.1 2.2 Reaven GM (December 1988). "Banting lecture 1988. Role of insulin resistance in human disease". Diabetes. 37 (12): 1595–607. doi:10.2337/diab.37.12.1595. PMID 3056758.
  3. ↑ 3.0 3.1 Alberti KG, Zimmet PZ (July 1998). "Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation". Diabet Med. 15 (7): 539–53. PMID 9686693.
  4. ↑ 4.0 4.1 Balkau B, Charles MA (May 1999). "Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR)". Diabet Med. 16 (5): 442–3. PMID 10342346.
  5. ↑ 5.0 5.1 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (May 2001). "Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)". JAMA. 285 (19): 2486–97. doi:10.1001/jama.285.19.2486. PMID 11368702.
  6. ↑ 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 6.10 6.11 6.12 6.13 Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F (October 2005). "Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement". Circulation. 112 (17): 2735–52. doi:10.1161/CIRCULATIONAHA.105.169404. PMID 16157765.
  7. ↑ 7.0 7.1 Alberti KG, Zimmet P, Shaw J (May 2006). "Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation". Diabet Med. 23 (5): 469–80. doi:10.1111/j.1464-5491.2006.01858.x. PMID 16681555.
  8. ↑ 8.00 8.01 8.02 8.03 8.04 8.05 8.06 8.07 8.08 8.09 8.10 8.11 Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC (October 2009). "Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity". Circulation. 120 (16): 1640–5. doi:10.1161/CIRCULATIONAHA.109.192644. PMID 19805654.
  9. ↑ 9.0 9.1 Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després JP, Ndumele CE, Vijayaraghavan K, Handelsman Y, Puckrein GA, Araneta MR (August 2015). "The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome". J Am Coll Cardiol. 66 (9): 1050–67. doi:10.1016/j.jacc.2015.06.1328. PMID 26314534.
  10. ↑ 10.00 10.01 10.02 10.03 10.04 10.05 10.06 10.07 10.08 10.09 10.10 10.11 10.12 Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, Coresh J, Mathew RO, Baker-Smith CM, Carnethon MR (November 2023). "Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association". Circulation. 148 (20): 1606–1635. doi:10.1161/CIR.0000000000001184. PMID 37807924 Check |pmid= value (help).
  11. ↑ 11.0 11.1 11.2 11.3 11.4 11.5 11.6 11.7 Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP (December 2023). "A multisociety Delphi consensus statement on new fatty liver disease nomenclature". Hepatology. 78 (6): 1966–1986. doi:10.1097/HEP.0000000000000520. PMID 37363821 Check |pmid= value (help).
  12. ↑ 12.0 12.1 12.2 12.3 12.4 Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JP, Brown WA, Stanford FC, Batterham RL, Farooqi IS, Farpour-Lambert NJ (March 2025). "Definition and diagnostic criteria of clinical obesity". Lancet Diabetes Endocrinol. 13 (3): 221–262. doi:10.1016/S2213-8587(24)00316-4. PMID 39824205 Check |pmid= value (help).
  13. ↑ 13.0 13.1 13.2 13.3 13.4 Kahn R, Buse J, Ferrannini E, Stern M (September 2005). "The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes". Diabetes Care. 28 (9): 2289–304. doi:10.2337/diacare.28.9.2289. PMID 16123508.
  14. ↑ 14.0 14.1 14.2 Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, Wong G, Bennett P, Shaw J, Caprio S (June 2007). "The metabolic syndrome in children and adolescents". Lancet. 369 (9579): 2059–61. doi:10.1016/S0140-6736(07)60958-1. PMID 17586288.
  15. ↑ 15.0 15.1 Ford ES (July 2005). "Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence". Diabetes Care. 28 (7): 1769–78. doi:10.2337/diacare.28.7.1769. PMID 15983333.
  16. ↑ 16.0 16.1 16.2 16.3 Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, Coresh J, Baker-Smith CM, Carnethon MR, Despres JP (November 2023). "A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association". Circulation. 148 (20): 1636–1664. doi:10.1161/CIR.0000000000001186. PMID 37807920 Check |pmid= value (help).
  17. ↑ Reaven GM (June 2006). "The metabolic syndrome: is this diagnosis necessary?". Am J Clin Nutr. 83 (6): 1237–47. doi:10.1093/ajcn/83.6.1237. PMID 16762930.
  18. ↑ 18.0 18.1 Petersen MC, Shulman GI (October 2018). "Mechanisms of Insulin Action and Insulin Resistance". Physiol Rev. 98 (4): 2133–2223. doi:10.1152/physrev.00063.2017. PMID 30067154.
  19. ↑ 19.0 19.1 19.2 19.3 19.4 19.5 Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP (May 2021). "Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association". Circulation. 143 (21): e984–e1010. doi:10.1161/CIR.0000000000000973. PMID 33882682 Check |pmid= value (help).
  20. ↑ 20.0 20.1 20.2 20.3 20.4 20.5 Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (May 2008). "The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline". J Clin Endocrinol Metab. 93 (5): 1526–40. doi:10.1210/jc.2008-0125. PMID 18334580.
  21. ↑ 21.0 21.1 21.2 21.3 21.4 21.5 21.6 21.7 Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA (September 2023). "Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome". J Clin Endocrinol Metab. 108 (10): 2447–2469. doi:10.1210/clinem/dgad463. PMID 37580314 Check |pmid= value (help).
  22. ↑ 22.0 22.1 22.2 22.3 Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, Mungai L, Oral EA, Patni N, Rother KI (December 2016). "The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline". J Clin Endocrinol Metab. 101 (12): 4500–4511. doi:10.1210/jc.2016-2466. PMID 27710244.
  23. ↑ 23.0 23.1 23.2 23.3 23.4 Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD (January 2020). "Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis". Lancet Psychiatry. 7 (1): 64–77. doi:10.1016/S2215-0366(19)30416-X. PMID 31860457.
  24. ↑ 24.0 24.1 24.2 Zhu R, Wang R, He J, Wang L, Chen H, Niu X, Sun Y, Guan Y, Gong Y, Zhang L, An P, Li K, Ren F, Xu W, Guo J (November 2024). "Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages by Social Determinants of Health". JAMA Netw Open. 7 (11): e2445309. doi:10.1001/jamanetworkopen.2024.45309. PMID 39556396 Check |pmid= value (help).
  25. ↑ Liang X, Or B, Tsoi MF, Cheung CL, Cheung BM (August 2023). "Prevalence of metabolic syndrome in the United States National Health and Nutrition Examination Survey 2011-18". Postgrad Med J. 99 (1175): 985–992. doi:10.1093/postmj/qgad008. PMID 36906842 Check |pmid= value (help).
  26. ↑ Hirode G, Wong RJ (June 2020). "Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016". JAMA. 323 (24): 2526–2528. doi:10.1001/jama.2020.4501. PMID 32573660 Check |pmid= value (help).
  27. ↑ Aggarwal R, Ostrominski JW, Vaduganathan M (June 2024). "Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020". JAMA. 331 (21): 1858–1860. doi:10.1001/jama.2024.6892. PMID 38717747 Check |pmid= value (help).
  28. ↑ 28.0 28.1 Noubiap JJ, Nansseu JR, Lontchi-Yimagou E, Nkeck JR, Nyaga UF, Ngouo AT, Tounouga DN, Tianyi FL, Foka AJ, Ndoadoumgue AL, Bigna JJ (March 2022). "Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis". Lancet Child Adolesc Health. 6 (3): 158–170. doi:10.1016/S2352-4642(21)00374-6. PMID 35051409 Check |pmid= value (help).
  29. ↑ Martin SS, Aday AW, Allen NB, Almarzooq ZI, Anderson CA, Arora P (February 2025). "2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association". Circulation. 151 (8): e41–e660. doi:10.1161/CIR.0000000000001303. PMID 39866113 Check |pmid= value (help).
  30. ↑ 30.0 30.1 30.2 30.3 American Diabetes Association Professional Practice Committee (January 2026). "3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2026". Diabetes Care. 49 (Supplement_1): S50–S60. doi:10.2337/dc26-S003. PMID 41358891 Check |pmid= value (help).
  31. ↑ 31.0 31.1 Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, George SM, Olson RD (November 2018). "The Physical Activity Guidelines for Americans". JAMA. 320 (19): 2020–2028. doi:10.1001/jama.2018.14854. PMID 30418471.
  32. ↑ 32.0 32.1 32.2 Lloyd-Jones DM, Allen NB, Anderson CA, Black T, Brewer LC, Foraker RE, Grandner MA, Lavretsky H, Perak AM, Sharma G, Rosamond W (August 2022). "Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association". Circulation. 146 (5): e18–e43. doi:10.1161/CIR.0000000000001078. PMID 35766027 Check |pmid= value (help).
  33. ↑ 33.0 33.1 Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW (September 2019). "2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Circulation. 140 (11): e596–e646. doi:10.1161/CIR.0000000000000678. PMID 30879355.
  34. ↑ Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Krist AH, Kubik M (August 2021). "Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement". JAMA. 326 (8): 736–743. doi:10.1001/jama.2021.12531. PMID 34427594 Check |pmid= value (help).
  35. ↑ Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW, Grossman DC, Kemper AR (September 2018). "Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: US Preventive Services Task Force Recommendation Statement". JAMA. 320 (11): 1163–1171. doi:10.1001/jama.2018.13022. PMID 30326502.
  36. ↑ Mangione CM, Barry MJ, Nicholson WK, Cabana M, Chelmow D, Coker TR, Davis EM, Donahue KE, Jaén CR, Kubik M (August 2022). "Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement". JAMA. 328 (8): 746–753. doi:10.1001/jama.2022.13044. PMID 35997723 Check |pmid= value (help).
  37. ↑ 37.0 37.1 37.2 Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, Blaha MJ, Carson AP, Chang AR, Ciemins E (February 2024). "Development and Validation of the American Heart Association's PREVENT Equations". Circulation. 149 (6): 430–449. doi:10.1161/CIRCULATIONAHA.123.067626. PMID 37947085 Check |pmid= value (help).
  38. ↑ Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ (September 2010). "The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis". J Am Coll Cardiol. 56 (14): 1113–32. doi:10.1016/j.jacc.2010.05.034. PMID 20863953.
  39. ↑ Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM (January 2007). "Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies". J Am Coll Cardiol. 49 (4): 403–14. doi:10.1016/j.jacc.2006.09.032. PMID 17258085.
  40. ↑ Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D (November 2012). "Metabolic syndrome and risk of cancer: a systematic review and meta-analysis". Diabetes Care. 35 (11): 2402–11. doi:10.2337/dc12-0336. PMID 23093685.
  41. ↑ 41.0 41.1 Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S (April 2005). "The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial". Ann Intern Med. 142 (8): 611–9. doi:10.7326/0003-4819-142-8-200504190-00009. PMID 15838067.
  42. ↑ 42.0 42.1 42.2 42.3 42.4 Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, Altieri MM, Bansal N, Bello NA, Bress AP (September 2025). "2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 152 (11): e114–e218. doi:10.1161/CIR.0000000000001356. PMID 40811497 Check |pmid= value (help).
  43. ↑ 43.0 43.1 Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (February 2002). "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin". N Engl J Med. 346 (6): 393–403. doi:10.1056/NEJMoa012512. PMID 11832527.
  44. ↑ Diabetes Prevention Program Research Group (November 2015). "Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study". Lancet Diabetes Endocrinol. 3 (11): 866–75. doi:10.1016/S2213-8587(15)00291-0. PMID 26377054.
  45. ↑ Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M (May 2001). "Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance". N Engl J Med. 344 (18): 1343–50. doi:10.1056/NEJM200105033441801. PMID 11333990.
  46. ↑ Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D (September 2004). "Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial". JAMA. 292 (12): 1440–6. doi:10.1001/jama.292.12.1440. PMID 15383514.
  47. ↑ Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J (June 2018). "Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts". N Engl J Med. 378 (25): e34. doi:10.1056/NEJMoa1800389. PMID 29897866.
  48. ↑ Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM (April 1997). "A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group". N Engl J Med. 336 (16): 1117–24. doi:10.1056/NEJM199704173361601. PMID 9099655.
  49. ↑ Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA (July 2013). "Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes". N Engl J Med. 369 (2): 145–54. doi:10.1056/NEJMoa1212914. PMID 23796131.
  50. ↑ Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE (June 2019). "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Circulation. 139 (25): e1082–e1143. doi:10.1161/CIR.0000000000000625. PMID 30586774.
  51. ↑ Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I (February 2010). "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials". Lancet. 375 (9716): 735–42. doi:10.1016/S0140-6736(09)61965-6. PMID 20167359.
  52. ↑ American Diabetes Association Professional Practice Committee (January 2026). "10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026". Diabetes Care. 49 (Suppl 1): S216–S245. doi:10.2337/dc26-S010. PMID 41358899 Check |pmid= value (help).
  53. ↑ Sattar N, Lee MM, Kristensen SL, Branch KR, Del Prato S, Khurmi NS, Lam CS, Lopes RD, McMurray JJ, Pratley RE, Rosenstock J, Gerstein HC (October 2021). "Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials". Lancet Diabetes Endocrinol. 9 (10): 653–662. doi:10.1016/S2213-8587(21)00203-5. PMID 34425083 Check |pmid= value (help).
  54. ↑ Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium (November 2022). "Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials". Lancet. 400 (10365): 1788–1801. doi:10.1016/S0140-6736(22)02074-8. PMID 36351458 Check |pmid= value (help).
  55. ↑ Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R (April 2016). "Pioglitazone after Ischemic Stroke or Transient Ischemic Attack". N Engl J Med. 374 (14): 1321–31. doi:10.1056/NEJMoa1506930. PMID 26886418.
  56. ↑ 56.0 56.1 American Diabetes Association Professional Practice Committee (January 2026). "8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes-2026". Diabetes Care. 49 (Suppl 1): S166–S182. doi:10.2337/dc26-S008. PMID 41358882 Check |pmid= value (help).
  57. ↑ Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MT, Wadden TA (March 2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity". N Engl J Med. 384 (11): 989–1002. doi:10.1056/NEJMoa2032183. PMID 33567185 Check |pmid= value (help).
  58. ↑ Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A (July 2022). "Tirzepatide Once Weekly for the Treatment of Obesity". N Engl J Med. 387 (3): 205–216. doi:10.1056/NEJMoa2206038. PMID 35658024 Check |pmid= value (help).
  59. ↑ Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM (August 2023). "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial". Lancet. 402 (10402): 613–626. doi:10.1016/S0140-6736(23)01200-X. PMID 37385275 Check |pmid= value (help).
  60. ↑ Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF (December 2023). "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes". N Engl J Med. 389 (24): 2221–2232. doi:10.1056/NEJMoa2307563. PMID 37952131 Check |pmid= value (help).
  61. ↑ Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, de Luca M, Faria SL, Goodpaster KP, Haddad A (December 2022). "2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery". Surg Obes Relat Dis. 18 (12): 1345–1356. doi:10.1016/j.soard.2022.08.013. PMID 36280539 Check |pmid= value (help).
  62. ↑ Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, Navaneethan SD, Singh RP, Pothier CE, Nissen SE, Kashyap SR (February 2017). "Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes". N Engl J Med. 376 (7): 641–651. doi:10.1056/NEJMoa1600869. PMID 28199805.
  63. ↑ Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B (August 2007). "Effects of bariatric surgery on mortality in Swedish obese subjects". N Engl J Med. 357 (8): 741–52. doi:10.1056/NEJMoa066254. PMID 17715408.
  64. ↑ Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, Ahlin S, Anveden Å, Bengtsson C, Bergmark G (January 2012). "Bariatric surgery and long-term cardiovascular events". JAMA. 307 (1): 56–65. doi:10.1001/jama.2011.1914. PMID 22215166.
  65. ↑ Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D (September 2021). "2021 ESC Guidelines on cardiovascular disease prevention in clinical practice". Eur Heart J. 42 (34): 3227–3337. doi:10.1093/eurheartj/ehab484. PMID 34458905 Check |pmid= value (help).
  66. ↑ Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (April 2024). "KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease". Kidney Int. 105 (4S): S117–S314. doi:10.1016/j.kint.2023.10.018. PMID 38490803 Check |pmid= value (help).
  67. ↑ American Diabetes Association Professional Practice Committee (January 2026). "11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026". Diabetes Care. 49 (Suppl 1): S246–S260. doi:10.2337/dc26-S011. PMID 41358881 Check |pmid= value (help).
  68. ↑ Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AM, Bugianesi E, Rinella ME, Roden M, Ratziu V (May 2025). "Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis". N Engl J Med. 392 (21): 2089–2099. doi:10.1056/NEJMoa2413258. PMID 40305708 Check |pmid= value (help).
  69. ↑ Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME (February 2024). "A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis". N Engl J Med. 390 (6): 497–509. doi:10.1056/NEJMoa2309000. PMID 38324483 Check |pmid= value (help).

Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Metabolic_syndrome&oldid=1745857"